An inflammatory cytokine signature helps predict COVID-19 severity and death
By
Diane Marie Del Valle,
Seunghee Kim-schulze,
Huang Hsin-hui,
Noam D Beckmann,
Sharon Nirenberg,
Bo Wang,
Yonit Lavin,
Talia Swartz,
Deepu Madduri,
Aryeh Stock,
Thomas Marron,
Hui Xie,
Manish Kumar Patel,
Oliver van Oekelen,
Adeeb H Rahman,
Patricia Kovatch,
Judith Aberg,
Eric Schadt,
Sundar Jagannath,
Madhu Mazumdar,
Alexander Charney,
Adolfo Firpo-Betancourt,
Damodara Rao Mendu,
Jeffrey Jhang,
David Reich,
Keith Sigel,
Carlos Cordon-Cardo,
Marc Feldmann,
Samir Parekh,
Miriam Merad,
Sacha Gnjatic
Posted 30 May 2020
medRxiv DOI: 10.1101/2020.05.28.20115758
The COVID-19 pandemic caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to more than 100,000 deaths in the United States. Several studies have revealed that the hyper-inflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum IL-6, IL-8, TNF-, and IL-1{beta} in hospitalized COVID-19 patients upon admission to the Mount Sinai Health System in New York. Patients (n=1484) were followed up to 41 days (median 8 days) and clinical information, laboratory test results and patient outcomes were collected. In 244 patients, cytokine measurements were repeated over time, and effect of drugs could be assessed. Kaplan-Meier methods were used to compare survival by cytokine strata, followed by Cox regression models to evaluate the independent predictive value of baseline cytokines. We found that high serum IL-6, IL-8, and TNF- levels at the time of hospitalization were strong and independent predictors of patient survival. Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF- serum levels remained independent and significant predictors of disease severity and death. We propose that serum IL-6 and TNF- levels should be considered in the management and treatment of COVID-19 patients to stratify prospective clinical trials, guide resource allocation and inform therapeutic options. We also propose that patients with high IL-6 and TNF- levels should be assessed for combinatorial blockade of pathogenic inflammation in this disease.
Download data
- Downloaded 4,737 times
- Download rankings, all-time:
- Site-wide: 2,148
- In infectious diseases: 478
- Year to date:
- Site-wide: 6,047
- Since beginning of last month:
- Site-wide: 8,491
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!